Page last updated: 2024-12-06

ticrynafen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ticrynafen is a non-steroidal anti-inflammatory drug (NSAID) that was developed in the 1970s. It was initially marketed as a treatment for rheumatoid arthritis, but was later withdrawn from the market due to concerns about its hepatotoxicity. Ticrynafen is a potent inhibitor of prostaglandin synthesis, which is believed to be the mechanism by which it exerts its anti-inflammatory effects. It is also a weak inhibitor of cyclooxygenase (COX), the enzyme responsible for the production of prostaglandins. Ticrynafen is synthesized by a multi-step process involving the reaction of 2-chloro-4-nitrobenzoic acid with 2-amino-4-methylphenol. The resulting compound is then reacted with sodium hydroxide to form the sodium salt of ticrynafen. Ticrynafen is studied because of its potential therapeutic benefits, particularly for the treatment of inflammatory conditions. However, its use is limited due to its hepatotoxicity. Researchers are continuing to investigate the mechanisms by which ticrynafen exerts its effects and to develop safer and more effective alternatives.'

Ticrynafen: A novel diuretic with uricosuric action. It has been proposed as an antihypertensive agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tienilic acid : An aromatic ketone that is 2,3-dichlorophenoxyacetic acid in which the hydrogen at position 4 on the benzene ring is replaced by a thiophenecarbonyl group. A loop diuretic used to treat hypertension, it was withdrawn from the market in 1982 due to links with hepatitis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2-phosphonatoglycolate(3-) : Trianion of 2-phosphoglycolic acid arising from deprotonation of the carboxy and phosphate groups; major species at pH 7.3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID38409
CHEMBL ID267744
CHEBI ID9590
SCHEMBL ID123608
MeSH IDM0021527
PubMed CID24916760
CHEBI ID58033
MeSH IDM0021527

Synonyms (108)

Synonym
{[2,3-dichloro-4-(2-thienylcarbonyl)phenyl]oxy}acetic acid
4-(2-theonyl)-2,3-dichlorphenoxyessigsaeure [german]
einecs 254-826-3
ticrynafen [usan]
acidum tienilicum [inn-latin]
ce 3624
acide tienilique [inn-french]
anp 3624
diflurex
acido tienilico [inn-spanish]
fr 3068
selacryn
skf 62698
ccris 5489
tienilico acido [spanish]
ticrex
acetic acid, (2,3-dichloro-4-(2-thienylcarbonyl)phenoxy)-
(2,3-dichloro-4-(2-thienylcarbonyl)phenoxy)acetic acid
brn 1260086
ticrynafen
tienilic acid
40180-04-9
DB04831
thienylic acid
NCGC00159454-02
NCGC00159454-03
4-(2-thienylketo)-2,3-dichlorophenoxyacetic acid
(2,3-dichloro-4-(2-thenoyl)phenoxy)acetic acid
(2,3-dichloro-4-(2-thiophenecarbonyl)phenoxy)acetic acid
tienilic acid (inn)
D02386
selacryn (tn)
ticrynafen (usan)
[2,3-dichloro-4-(thiophene-2-carbonyl)-phenoxy]-acetic acid(tienilic acid)
[2,3-dichloro-4-(thiophene-2-carbonyl)-phenoxy]-acetic acid
[2,3-dichloro-4-(thiophene-2-carbonyl)-phenoxy]-acetic acid(ticrynafen)
bdbm50090674
[2,3-dichloro-4-(thiophene-2-carbonyl)-phenoxy]-acetic acid (tienilic acid)
AKOS000280732
2-[2,3-dichloro-4-(thiophene-2-carbonyl)phenoxy]acetic acid
chebi:9590 ,
CHEMBL267744 ,
sk&f 62698
NCGC00159454-04
[2,3-dichloro-4-(2-thienylcarbonyl)phenoxy]acetic acid
tox21_111682
tox21_111681
dtxcid603670
dtxsid4023670 ,
cas-40180-04-9
FT-0675229
hc95205sy4 ,
acidum tienilicum
acide tienilique
acido tienilico
tienilico acido
4-(2-theonyl)-2,3-dichlorphenoxyessigsaeure
tienilic acid [inn]
5-18-02-00008 (beilstein handbook reference)
unii-hc95205sy4
BRD-K34098590-001-01-3
tienilic acid [mart.]
ticrynafen [mi]
sk&f-62698
tienilic acid [who-dd]
SCHEMBL123608
ticrynafen, tienilic acid
7Z-0042
AGHANLSBXUWXTB-UHFFFAOYSA-N
2,3-dichloro-4-(2-thienylcarbonyl)-phenoxyacetic acid
ticrynafan
[2,3-dichloro-4-(thiophene-2-carbonyl)-phenoxyl]-acetic acid
HMS3650C20
mfcd00867339
acetic acid, [2,3-dichloro-4-(2-thienylcarbonyl)phenoxy]-
tienilic acid, >=98% (hplc)
2-{2,3-dichloro-4-[(thiophen-2-yl)carbonyl]phenoxy}acetic acid
2-(2,3-dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid
CS-0012688
sr-00000000556
SR-00000000556-2
Q7801054
NCGC00159454-09
tienilic-acid
anp 362
2-(2,3-dichloro-4-(thiophene-2-carbonyl)phenoxy)aceticacid
HY-21065
SY258870
2,3-dichloro-4-[(thiophen-2-yl)carbonyl]phenoxyacetic acid
2-p-glycolate
2-phosphoglycolate
1AMK
2J27
2V2H
2RKA
2V2C
2-(phosphonatooxy)acetate
2-phosphonatoglycolate(3-)
CHEBI:58033
2-phosphonatoglycolate trianion
(phosphonatooxy)acetate
2-phosphonatoglycolate
3MOH
Q27125138
DTXSID301281498
acetic acid, 2-(phosphonooxy)-, ion(3-)
13116-18-2
2-phosphonatooxyacetate

Research Excerpts

Overview

Ticrynafen is an orally administered diuretic that is similar to the thiazides in its therapeutic actions. It increases urate excretion and lowers serum uric acid levels.

ExcerptReferenceRelevance
"Ticrynafen is an inhibitor of reabsorption of sodium and uric acid by the kidney."( Pharmacokinetics and mode of action of tienilic acid.
Beg, M; Maass, AR; Snow, IB; Stote, RM, 1982
)
0.99
"Ticrynafen is an orally administered diuretic that is similar to the thiazides in its therapeutic actions, but unlike the thiazides, it increases urate excretion and lowers serum uric acid levels. "( Evaluation of a new uricosuric diuretic--ticrynafen.
Kosman, ME, 1979
)
1.97

Toxicity

Ticrynafen, indacrinone, ethacrynic acid and A-49816, an investigational compound, were found to be toxic in hepatocyte cultures. With the exception of indacinone, paralleling the experience in humans.

ExcerptReferenceRelevance
" Overall, adverse reactions characterized as probably drug-related or questinably drug-related were reported in 28% of patients treated with tienilic acid, 24% treated with hydrochlorothiazide, 25% of patients treated with probenecid and 33% treated with placebo."( Safety of tienilic acid.
Beg, MA; Ragland, R, 1979
)
0.26
" Ticrynafen, indacrinone, ethacrynic acid and A-49816, an investigational compound, were found to be toxic in hepatocyte cultures; thus, with the exception of indacrinone, paralleling the experience in humans."( Toxicity of uricosuric diuretics in rat hepatocyte culture.
el Masry, S; Gray, PD; Janicki, RS; Luther, RR; Tolman, KG, 1989
)
1.19
" The results of the study indicate that ticrynafen was minimally toxic to the hepatocytes."( Lack of cytotoxicity of ticrynafen in primary cultures of rat liver cells.
Acosta, D; Bock, A; Lewis, W; Mitchell, DB; Santone, KS, 1982
)
0.84
" Results of qualitative and quantitative covalent binding of tienilic acid metabolite(s) to human liver microsomes were then compared to those obtained with two drugs leading to direct toxic hepatitis, namely, acetaminophen and chloroform."( Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs.
Ballet, F; Beaune, PH; Bonierbale, E; Catinot, R; Challine, D; Dansette, PM; Gautier, JC; Lecoeur, S; Mansuy, D; Valadon, P,
)
0.13
"Two closely related compounds, a diuretic drug tienilic acid (TA) and its isomer TAI have been found to exert very different toxic effects."( Molecular structure and hepatotoxicity: compared data about two closely related thiophene compounds.
Mansuy, D, 1997
)
0.3
" Drug-induced hepatitis is generally divided into two categories: acute hepatitis in which the drug or a metabolite destroys a vital target in the cell; immunoallergic hepatitis in which the drug triggers an adverse immune response directed against the liver."( Drug-induced immunotoxicity.
Beaune, PH; Bonierbale, E; Dansette, PM; Mansuy, D; Minoletti, C; Pessayre, D,
)
0.13
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic parameters found differed only slightly from those reported in the literature, as there was faster absorption and a shorter half-life."( Pharmacokinetic and pharmacodynamic studies of tienilic acid in healthy volunteers.
Gribnau, FW; Kerremans, AL; Tan, Y; van Ginneken, CA, 1982
)
0.26

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" When warranted, dosage was increased to a maximum of 500 mg of tienilic acid and 100 mg of hydrochlorothiazide daily."( Long-term usage of tienilic acid in essential hypertension.
Beg, MA; Noble, RE, 1979
)
0.26
" A twice-daily regimen was considerably more effective than a single morning dosage in reduction of plasma urate, though both regimens were equally effective in antihypertensive potency."( Controlled inpatient study of tienilic acid in treatment of gout and hypertension.
Reardon, JA; Scott, JT, 1980
)
0.26
" The increase in the serum ALT level and hepatocyte necrosis resulting from the combined dosing of BSO and tienilic acid was prevented by ABT, despite a low hepatic GSH level."( Involvement of cytochrome P450-mediated metabolism in tienilic acid hepatotoxicity in rats.
Hattori, C; Jindo, T; Kataoka, H; Kato, M; Manabe, S; Maru, C; Mori, K; Nishiya, T; Suzuki, T; Tanaka, Y, 2008
)
0.35
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
loop diureticA diuretic that acts on the ascending loop of Henle in the kidney.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
hepatotoxic agentA role played by a chemical compound exihibiting itself through the ability to induce damage to the liver in animals.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
thiophenesCompounds containing at least one thiophene ring.
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
monocarboxylic acidAn oxoacid containing a single carboxy group.
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
organophosphate oxoanionAn organic phosphoric acid derivative in which one or more oxygen atoms of the phosphate group(s) has been deprotonated.
monocarboxylic acid anionA carboxylic acid anion formed when the carboxy group of a monocarboxylic acid is deprotonated.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (15)

PathwayProteinsCompounds
glycolysis IV (plant cytosol)1347
superpathway of cytosolic glycolysis (plants), pyruvate dehydrogenase and TCA cycle2856
photorespiration823
Rubisco shunt632
superpathway of anaerobic sucrose degradation3360
nitrate reduction X (dissimilatory, periplasmic)517
superpathway of cytosolic glycolysis (plants), pyruvate dehydrogenase and TCA cycle2459
superpathway of glycolysis and the Entner-Doudoroff pathway2358
Rubisco shunt832
superpathway of glycolysis, pyruvate dehydrogenase, TCA, and glyoxylate bypass3989
photosynthetic 3-hydroxybutanoate biosynthesis (engineered)6373
glycerol-3-phosphate to cytochrome bo oxidase electron transfer529
superpathway of N-acetylneuraminate degradation3979
gluconeogenesis I2862
superpathway of hexitol degradation (bacteria)2960
glycolysis II (from fructose 6-phosphate)2149
glycolysis I (from glucose 6-phosphate)3751
glycolysis IV (plant cytosol)747
superpathway of anaerobic sucrose degradation2661
photorespiration1723

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00710.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency19.90540.140911.194039.8107AID2451
AR proteinHomo sapiens (human)Potency17.95000.000221.22318,912.5098AID743036
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.88130.000229.305416,493.5996AID743075
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2C9 Homo sapiens (human)Ki7.65000.00031.684210.0000AID54405; AID589256
Chain A, TRIOSE PHOSPHATE ISOMERASELeishmania mexicanaKi50.000050.000050.000050.0000AID977610
Chain A, TRIOSEPHOSPHATE ISOMERASE GLYCOSOMALTrypanosoma brucei bruceiKi300.0000300.0000300.0000300.0000AID977610
Chain A, Phosphoenolpyruvate carboxykinase, cytosolic [GTP]Rattus norvegicus (Norway rat)Ki1,000.00001,000.00001,000.00001,000.0000AID977610
Chain A, Phosphoenolpyruvate carboxykinase, cytosolic [GTP]Rattus norvegicus (Norway rat)Ki1,000.00001,000.00001,000.00001,000.0000AID977610
Chain A, Phosphoenolpyruvate carboxykinase, cytosolic [GTP]Rattus norvegicus (Norway rat)Ki1,000.00001,000.00001,000.00001,000.0000AID977610
Chain A, Phosphoenolpyruvate carboxykinase, cytosolic [GTP]Rattus norvegicus (Norway rat)Ki1,000.00001,000.00001,000.00001,000.0000AID977610
Chain A, Phosphoenolpyruvate carboxykinase, cytosolic [GTP]Rattus norvegicus (Norway rat)Ki1,000.00001,000.00001,000.00001,000.0000AID977610
Chain A, Triosephosphate Isomerase GlycosomalTrypanosoma brucei bruceiKi280.0000170.0000280.0000390.0000AID977610
Chain A, TRIOSEPHOSPHATE ISOMERASE GLYCOSOMALTrypanosoma brucei bruceiKi280.0000170.0000280.0000390.0000AID977610
Chain A, Phosphoenolpyruvate carboxykinase, cytosolic [GTP]Rattus norvegicus (Norway rat)Ki1,460.00001,460.00001,460.00001,460.0000AID977610
Chain A, Phosphoenolpyruvate carboxykinase, cytosolic [GTP]Rattus norvegicus (Norway rat)Ki1,460.00001,460.00001,460.00001,460.0000AID977610
Chain A, Phosphoenolpyruvate carboxykinase, cytosolic [GTP]Rattus norvegicus (Norway rat)Ki1,460.00001,460.00001,460.00001,460.0000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (110)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1217729Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID60412Diuretic activity was measured after oral administration in conscious water loaded dogs at 20 mg/kg after 1 hr1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
[(3-aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series.
AID196141Natriuretic activity in rats at 81 mg/kg of dosage; mequiv of Na1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics.
AID62821Compound was tested for diuretic activity in dogs at 5 mg/kg dose after oral administration measured as microequivalent of Cl-/minute1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics.
AID62822Compound was tested for diuretic activity in dogs at 5 mg/kg dose after oral administration measured as microequivalent of K+/minute1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics.
AID60418The diuretic activity of compound was measured after oral administration in conscious water loaded dogs at 5 mg/kg after 5h; Micro equiv of Na+/kg1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
[(3-aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID24131urate excreted in 6 female dogs during 0-6 hr1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Substituted 5,6-dihydrofuro[3,2-f]-1,2-benzisoxazole-6-carboxylic acids: high-ceiling diuretics with uricosuric activity.
AID1217708Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID60417The diuretic activity of compound was measured after oral administration in conscious water loaded dogs at 5 mg/kg after 4 hr; Micro equiv of Na+/kg1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
[(3-aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID63164Diuretic activity in dogs following 5 mg/kg i.v. administration.1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics.
AID224546Diuretic activity in saline loaded mice, activity is expressed as the sodium present in urine as mean milli equivalent/kg per 5 hr at 64 mg/kg oral dose1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
[(6,7-Dichlorobenzo[b]thien-5-yl)oxy]acetic acids and 1,1-dioxides. 1. A structurally novel class of diuretics with hypotensive activity.
AID1216822Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siScramble at 50 to 200 uM after 24 hrs by ATP assay2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1217707Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1779666Agonist activity at human BLT2 overexpressed in CHO-K1 cells assessed as accumulation of inositol monophosphate measured after 90 mins by HTRF assay2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Discovery of Irbesartan Derivatives as BLT2 Agonists by Virtual Screening.
AID62823Compound was tested for diuretic activity in dogs at 5 mg/kg dose after oral administration measured as microequivalent of Na+/minute1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1217705Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID63168Compound was tested for diuretic activity in dogs at 5 mg/kg dose after intravenous administration, activity is expressed as urine volume; 0.6/21981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID62696Compound was tested for diuretic activity in dogs at 5 mg/kg dose after intravenous administration measured as microequivalent of Na+/minute; 22/144 (Control/Drug treated)1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics.
AID1217704Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID17334Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Substituted 5,6-dihydrofuro[3,2-f]-1,2-benzisoxazole-6-carboxylic acids: high-ceiling diuretics with uricosuric activity.
AID17331Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Substituted 5,6-dihydrofuro[3,2-f]-1,2-benzisoxazole-6-carboxylic acids: high-ceiling diuretics with uricosuric activity.
AID589256Mechanism based inhibition of human cytochrome P450 2C92005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID60419The diuretic activity of compound was measured after oral administration in conscious water loaded dogs at 5 mg/kg after 6 h; Micro equiv of Na+/kg1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
[(3-aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series.
AID196139Natriuretic activity in rats at 3 mg/kg of dosage; mequiv of Na1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1217711Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1217727Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1217728Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1217709Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID189693Diuretic activity after peroral administration of 100 mg/Kg in rats1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Studies on uricosuric diuretics. 4. Three-dimensional structure-activity relationships and receptor mapping of (aryloxy)acetic acid diuretics.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID54405Binding affinity measured on human cytochrome P450 2C9 (CYP2C9) enzyme2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID140710Compound was tested for diuretic activity after oral administration of 64 mg/kg in saline-loaded mice (vehicle control value=0.1)1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Heterocyclic oxyacetic acid diuretics: indazole, benzisothiazole, and benzisothiazole 1,1-dioxide analogues of [[7-chloro-3-(2-fluorophenyl)-1,2-benzisoxazol-6-yl]oxy]acetic acid.
AID442514Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1216819Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siNrf2 at 50 to 200 uM after 24 hrs by ATP assay2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID60416The diuretic activity of compound was measured after oral administration in conscious water loaded dogs at 5 mg/kg after 3 hr; Micro equiv of Na+/kg1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
[(3-aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series.
AID589190Mechanism based inhibition of human cytochrome P450 2C9, partition ratio2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1217720Time dependent inhibition of CYP2C9 (unknown origin) at 10 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID60415The diuretic activity of compound was measured after oral administration in conscious water loaded dogs at 5 mg/kg after 2 hr; Micro equiv of Na+/kg1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
[(3-aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series.
AID196142Natriuretic activity in rats at 9 mg/kg of dosage; mequiv of Na1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics.
AID51764Compound was tested for natriuretic activity in chimpanzee at 5 mg/kg dose activity is measured as microequivalent of Na+/minute; muequiv of Na+/min1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics.
AID60414The diuretic activity of compound was measured after oral administration in conscious water loaded dogs at 5 mg/kg after 1 hr; Micro equiv of Na+/kg1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
[(3-aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID20827Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 50 ml/kg perorally1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Substituted 5,6-dihydrofuro[3,2-f]-1,2-benzisoxazole-6-carboxylic acids: high-ceiling diuretics with uricosuric activity.
AID1216813Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siNrf2 at 100 to 200 uM after 24 hrs by WST-8 assay2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID17336Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Substituted 5,6-dihydrofuro[3,2-f]-1,2-benzisoxazole-6-carboxylic acids: high-ceiling diuretics with uricosuric activity.
AID62673Compound was tested for diuretic activity in dogs at 5 mg/kg dose after intravenous administration measured as microequivalent of Cl-/minute; 9/132 (Control/Drug treated)1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID193276Hypotensive activity was determined in Spontaneously hypertensive rats (SHR) and initial blood pressure was determined at 50 mg/kg oral dose1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
[(6,7-Dichlorobenzo[b]thien-5-yl)oxy]acetic acids and 1,1-dioxides. 1. A structurally novel class of diuretics with hypotensive activity.
AID233748Compound was tested for natriuretic activity in chimpanzee at 5 mg/kg dose activity is measured as ratio of clearance of urate / insulin; Curate/Cinulin1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics.
AID62679Compound was tested for diuretic activity in dogs at 5 mg/kg dose after intravenous administration measured as microequivalent of K+/minute; 3/8 (Control/Drug treated)1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID196138Natriuretic activity in rats at 27 mg/kg of dosage; mequiv of Na1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 3. 2,3-Dihydro-5-acyl-2-benzofurancarboxylic acids, a new class of uricosuric diuretics.
AID60420The diuretic activity of compound was measured after oral administration in conscious water loaded dogs at 5 mg/kg after 7h; Micro equiv of Na+/kg1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
[(3-aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID194007Hypotensive activity was determined in Spontaneously hypertensive rats (SHR) and peak decrease in systolic blood pressure on third day,2h post administration of 50 mg/kg oral dose was determined1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
[(6,7-Dichlorobenzo[b]thien-5-yl)oxy]acetic acids and 1,1-dioxides. 1. A structurally novel class of diuretics with hypotensive activity.
AID24128urate excreted in 4 Cebus monkey''s during 0-6 hr1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Substituted 5,6-dihydrofuro[3,2-f]-1,2-benzisoxazole-6-carboxylic acids: high-ceiling diuretics with uricosuric activity.
AID589087Mechanism based inhibition of human cytochrome P450 2C9 measured by tienilic acid 5-hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1217710Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID442515Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation at 50 uM2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.
AID1217712Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID117497The diuretic activity was measured after oral administration in saline loaded mice at 4 mg/kg after 5 hr1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
[(3-aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series.
AID117499The diuretic activity was measured after oral administration in saline loaded mice at 64 mg/kg after 5 hr1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
[(3-aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2008Acta crystallographica. Section D, Biological crystallography, Feb, Volume: 64, Issue:Pt 2
Structural studies show that the A178L mutation in the C-terminal hinge of the catalytic loop-6 of triosephosphate isomerase (TIM) induces a closed-like conformation in dimeric and monomeric TIM.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2008Biochemistry, Feb-19, Volume: 47, Issue:7
Differential inhibition of cytosolic PEPCK by substrate analogues. Kinetic and structural characterization of inhibitor recognition.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1999Protein engineering, Mar, Volume: 12, Issue:3
Structural and mutagenesis studies of leishmania triosephosphate isomerase: a point mutation can convert a mesophilic enzyme into a superstable enzyme without losing catalytic power.
AID1811Experimentally measured binding affinity data derived from PDB1999Protein engineering, Mar, Volume: 12, Issue:3
Structural and mutagenesis studies of leishmania triosephosphate isomerase: a point mutation can convert a mesophilic enzyme into a superstable enzyme without losing catalytic power.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2006Biochemistry, Dec-26, Volume: 45, Issue:51
Functional role of the conserved active site proline of triosephosphate isomerase.
AID1811Experimentally measured binding affinity data derived from PDB2006Biochemistry, Dec-26, Volume: 45, Issue:51
Functional role of the conserved active site proline of triosephosphate isomerase.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2010Biochemistry, Jun-29, Volume: 49, Issue:25
Increasing the conformational entropy of the Omega-loop lid domain in phosphoenolpyruvate carboxykinase impairs catalysis and decreases catalytic fidelity .
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (214)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990137 (64.02)18.7374
1990's33 (15.42)18.2507
2000's18 (8.41)29.6817
2010's23 (10.75)24.3611
2020's3 (1.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.39 (24.57)
Research Supply Index5.57 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials29 (12.50%)5.53%
Trials0 (0.00%)5.53%
Reviews14 (6.03%)6.00%
Reviews0 (0.00%)6.00%
Case Studies32 (13.79%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other157 (67.67%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]